Eupraxia Pharmaceuticals Reports Six-Month Symptom Data for Highest Dose Cohort in Eosinophilic Esophagitis Trial

Eupraxia Pharmaceuticals has released six-month symptom data from the highest dose cohort in its ongoing Phase 1b/2a RESOLVE trial, which is investigating a potential treatment for eosinophilic esophagitis (EoE). The trial focuses on evaluating the safety and efficacy of EP-104IAR, a drug candidate designed to address inflammation associated with EoE. The company reported findings from patients who received the highest dosage of the investigational therapy.

The data revealed changes in symptoms over a six-month period among participants in this specific cohort. Eupraxia Pharmaceuticals stated that the trial aims to assess both short-term and long-term impacts of EP-104IAR on individuals diagnosed with EoE, a chronic condition characterized by inflammation of the esophagus caused by an accumulation of eosinophils. The RESOLVE trial continues to monitor patient outcomes as part of its broader investigation into potential therapeutic options for managing this condition.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 17, 2026

Author

GOAI